Six Weeks of Breathlessness: A Natriuretic Peptide That Does Not Exclude

The trap: reflexively reading 340 as 'below 400, so not heart failure.' Natriuretic peptide interpretation is patient-specific, and this patient has three conditions that move the number in opposite directions.

Factors that lower NT-proBNP:

• Obesity. BMI 34 lowers natriuretic peptide concentrations substantially, via increased clearance and reduced synthesis. In obese patients, rule-in thresholds are effectively halved - a value around 200 pg/mL or above is often used to suggest heart failure. A 'normal' value in a thin patient is a borderline-abnormal value here.

Factors that raise NT-proBNP:

• Atrial fibrillation raises levels independent of filling pressures, so part of the 340 is rhythm, not ventricular wall stress.
• Chronic kidney disease (creatinine now 1.4 from 1.1) reduces clearance and raises levels.
• Age raises levels modestly.

Net reading: in a patient whose obesity should have pushed the value below 100, a value of 340 that is further inflated by AF and CKD is genuinely informative. It does not exclude heart failure - it modestly supports it. The peptide is not the diagnosis either way; it is a piece of evidence.

What the peptide cannot tell you: it does not distinguish HFrEF from HFpEF, does not grade severity reliably in AF, and does not separate cardiac from pulmonary causes when CKD is present. Those are imaging and echocardiographic questions.

Documentation point: record the BMI-adjusted interpretation in the note so that a future clinician does not discard the value as 'normal.'

1. Heart failure (HFpEF or HFrEF) - most likely.

• For: orthopnea, paroxysmal nocturnal dyspnea, JVD at 12 cm, bibasilar crackles, bilateral pitting edema, AF, long-standing diabetes and hypertension, obesity, rising creatinine (cardiorenal), and an NT-proBNP that is elevated once BMI is accounted for. The subacute 6-week course fits decompensation with a trigger.
• Against: no murmur or S3 documented, and crackles alone are nonspecific. Absence of those does not meaningfully lower probability.
• Look for the trigger: dietary sodium, new AF with loss of atrial kick, NSAID use, anemia (Hb 11.1), or nonadherence.

2. COPD or smoking-related lung disease with cor pulmonale.

• For: 30 pack-years, hypoxemia at 92%, dyspnea on exertion, edema that could be right heart failure from pulmonary hypertension.
• Against: orthopnea and PND are much more characteristic of left-sided filling pressures than of airflow obstruction; COPD alone rarely produces JVD of this degree with clear lungs between crackles. Edema in COPD usually requires cor pulmonale, which is a late finding.
• Test it: spirometry once euvolemic; do not rely on it acutely.

3. Volume overload from CKD/anemia, or a mixed picture.

• For: creatinine rose from 1.1 to 1.4, hemoglobin 11.1, both can produce dyspnea and edema.
• Against: CKD-associated volume overload usually is not this rapid or this symptomatic with a normal-ish creatinine, and anemia of 11.1 rarely produces orthopnea.
• Also keep on the list: obstructive sleep apnea/obesity hypoventilation (BMI 34, nocturnal symptoms), hypothyroidism, and constrictive pericarditis if JVD seems disproportionate to the rest of the exam.

Reasoning discipline: these are not mutually exclusive. The most probable formulation is heart failure with AF as both a contributor and a consequence, with COPD as a comorbidity that will need its own evaluation once volume status is controlled.

Primary test: transthoracic echocardiogram with Doppler.

Why it is the highest-yield single study here:

• It answers the question the peptide cannot - ejection fraction, wall motion, LV hypertrophy, chamber sizes.
• It provides diastolic parameters and estimated filling pressures, which is how HFpEF is identified in a patient with this risk profile.
• It evaluates valves (a previously unheard murmur may be present) and estimates pulmonary pressures, which addresses the COPD/cor pulmonale branch of the differential.
• It looks for pericardial disease if the JVD is out of proportion.
• The result changes therapy directly: HFrEF triggers guideline-directed therapy, HFpEF triggers SGLT2 inhibitor plus diuretic plus comorbidity control.

Ordered alongside, with reasons:

• Chest radiograph - cardiomegaly, pulmonary vascular congestion, effusions, and alternative pulmonary pathology; cheap and immediately available.
• ECG (already done) plus rhythm monitoring - rate control in AF is part of the management, not just the diagnosis.
• CBC, comprehensive metabolic panel, TSH, iron studies (ferritin and transferrin saturation) - anemia and iron deficiency alter both symptoms and treatment; TSH excludes a reversible cause.
• Urinalysis with albumin-to-creatinine ratio - the rising creatinine needs a cause, and albuminuria changes the medication plan.
• Spirometry deferred until euvolemic, so results are interpretable.

Do not order: routine serial natriuretic peptides to 'trend' the diagnosis, and do not start diuresis before documenting baseline weight, orthostatics, and renal function.

Immediate management bridge: modest loop diuretic with daily weights, strict return precautions, and reassessment in 48-72 hours, with the caveat that aggressive diuresis in a patient with a rising creatinine and possible COPD requires close follow-up rather than a large single dose.